Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

1 Dupilumab is being jointly developed by Regeneron ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's ...

1 Dupilumab is being jointly developed by Regeneron ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital, presented a session at ...

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...

We're determined to ensure that patients won't have to choose or make trade-off between efficacy, safety, convenience and cost ... to what has been reported for dupilumab. Though as we have ...